Wall Street brokerages forecast that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report sales of $40.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The lowest sales estimate is $38.81 million and the highest is $42.44 million. Enanta Pharmaceuticals reported sales of $44.05 million during the same quarter last year, which indicates a negative year over year growth rate of 7.2%. The business is scheduled to report its next earnings report on Tuesday, May 14th.

On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $216.24 million for the current year, with estimates ranging from $210.26 million to $227.39 million. For the next year, analysts forecast that the company will report sales of $195.42 million, with estimates ranging from $179.24 million to $213.99 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.21). Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The business had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. During the same period in the previous year, the firm earned $0.59 EPS. The company’s revenue was up 83.4% on a year-over-year basis.

ENTA has been the subject of a number of recent research reports. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, November 20th. ValuEngine downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 8th. TheStreet downgraded shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, December 3rd. Finally, Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, November 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $100.00.

Shares of ENTA stock opened at $95.95 on Thursday. Enanta Pharmaceuticals has a 1 year low of $64.08 and a 1 year high of $127.77. The firm has a market cap of $1.76 billion, a PE ratio of 27.57 and a beta of 1.27.

In related news, VP Yat Sun Or sold 27,684 shares of the company’s stock in a transaction on Monday, February 11th. The shares were sold at an average price of $89.39, for a total value of $2,474,672.76. Following the completion of the transaction, the vice president now owns 320,169 shares of the company’s stock, valued at approximately $28,619,906.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Nathaniel S. Gardiner sold 3,270 shares of the company’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $95.28, for a total transaction of $311,565.60. Following the completion of the transaction, the vice president now directly owns 320,169 shares of the company’s stock, valued at approximately $30,505,702.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,688 shares of company stock valued at $3,482,376. Insiders own 11.35% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its holdings in Enanta Pharmaceuticals by 64.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after buying an additional 249 shares during the period. Bank of Montreal Can lifted its stake in Enanta Pharmaceuticals by 33.0% in the 4th quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares in the last quarter. Smith Asset Management Group LP purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth $173,000. People s United Financial Inc. purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth $212,000. Finally, Pacer Advisors Inc. purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth $230,000. 87.23% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: What is an SEC Filing?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.